Prostate Cancer Panel
Use
This panel is designed for individuals with a suspected or confirmed hereditary prostate cancer diagnosis, including those diagnosed with metastatic or high-risk prostate cancer, early-onset prostate cancer diagnosed before age 55, or those with a family history involving prostate and related cancers such as breast, ovarian, and pancreatic cancer across first-, second-, or third-degree relatives.
Special Instructions
New York approved. This test uses NGS with CNV on the PGselect Platform. Include detailed clinical records and relevant family history to aid interpretation. Orders require completion of a test requisition form and accompanying clinical features checklist or equivalent documentation.
Limitations
The results of this panel may not detect all genetic variants associated with prostate cancer, as it is dependent on the quality and depth of sequencing and the regions covered. Limitations also include potential missed CNV variants if they do not encompass the targeted regions comprehensively. Interpretation of results requires a complete clinical overview and may necessitate validation via additional testing.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided